factual

Negative net present value drives pharma exit

A London School of Economics study found that a big pharmaceutical company investing in a new antibiotic faces a net present value of negative $50 million—an expected loss—which is why companies are bundling and selling off their anti-infective units and why the 75-year government-pharma partnership is dissolving.

factualpending

Speaker

Matt McCarthy

Evidence Quote

“the net present value is negative $50 million they can expect to lose that much money”

Source

166 - The Plague Years— Making Sense with Sam Harris
Created: 6/14/2026, 2:12:29 AM

Your notes

Loading notes...